Philips Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
Receives FDA clearance to market its CVI-Q (color velocity imaging-quantification) technique, which the company claims is the first color flow ultrasound method "for directly quantifying the velocity and volume of blood flow in vessels." Using Philips' proprietary technology of "time domain signal processing," CVI-Q can provide measurements that improve physicians' precision in "diagnosing and determining the best treatment for vascular disorders," Philips says
You may also be interested in...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.